In a reader survey, researchers and core lab staff share how they think cores are doing.

Meetings and Deadlines

Premium

Upcoming events

SRI International has updated its BioCyc database collection to include a mobile application for remote access, as well as additional repositories that support researchers studying genomes and metabolic pathways.

A cadre of AMP members descended on Capitol Hill to educate legislators on what they believe would be a negative impact of FDA regulation on the MDx industry.

NEW YORK (GenomeWeb) – People armed with genetic information about their risk for developing high blood were more inclined to cut down on their salt intake, researchers from the University of Toronto reported in a study

NEW YORK (GenomeWeb) – Becton Dickinson said today that it has entered into a $9.1 bridge loan agreement to ensure that it will be able to fund its $12.2 billion acquisition of CareFusion.

Note to Readers

Premium

Look out next week for a major GenomeWeb redesign that will include a change to our weekly premium newsletters. ProteoMonitor will no longer publish on Fridays. Instead, you'll receive the Proteomics Bulletin, one of 10 new weekly topic-specific news mailings that will be available to all GenomeWeb Premium subscribers. You will be able to opt into any of the weekly mailings that you choose, so please visit your My Account page next week to set your email preferences!

Uhlén discusses the recent Human Protein Atlas release and future plans for the project.

Having struggled unsuccessfully for several years (and through several management teams) to drive adoption of its OVA1 ovarian cancer test, Vermillion said this week that it is shifting to a new strategy in which it will seek to broaden its business beyond proteomics.

Pages

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.